Table 1.
Baseline characteristics of patients with IgA nephropathy
| All Patients (N=985) | Nephrotic Syndrome (n=100) | Non-Nephrotic Syndrome (n=885) | P | |
|---|---|---|---|---|
| Age (yr) | 37.7±12.8 | 39.5±15.0 | 37.4±12.5 | 0.12 |
| Male sex, n (%) | 459 (46.6) | 44 (44.0) | 412 (46.6) | 0.83 |
| Hypertension, n (%) | 125 (12.7) | 20 (20.0) | 105 (11.9) | 0.03 |
| Diabetes, n (%) | 14 (1.4) | 4 (2.9) | 10 (1.1) | 0.08 |
| Hepatitis B surface antigen positivity, n (%) | 31 (3.1) | 7 (7.0) | 24 (2.7) | 0.04 |
| Systolic BP (mmHg) | 123.7±34.8 | 131.9±15.1 | 122.1±34.8 | 0.01 |
| Diastolic BP (mmHg) | 76.8±8.9 | 81.1±10.3 | 76.2±8.7 | <0.001 |
| Mean arterial BP (mmHg) | 92.4±14.3 | 98.0±10.9 | 91.8±14.5 | <0.001 |
| Laboratory measurements | ||||
| 24-h protein excretion (g/d) | 1.31 (0.0–16.10) | 5.80 (3.67–16.10) | 1.5 (0.0–3.40) | <0.001 |
| random UPCR (g/g) | 1.05 (0.01–18.20) | 5.74 (3.50–18.20) | 0.98 (0.01–3.74) | <0.001 |
| SCr (mg/dl) | 1.0±0.6 | 1.2±0.4 | 0.9±0.3 | <0.001 |
| eGFR (ml/min per 1.73 m2) | 84.1±39.1 | 69.4±17.5 | 88.5±32.5 | <0.001 |
| serum albumin (g/dl) | 4.1±0.7 | 2.8±0.6 | 4.2±0.5 | <0.001 |
| total cholesterol (mg/dl) | 190.5±51.3 | 267.0±76.2 | 181.8±39.1 | <0.001 |
| Follow-up duration (mo) | 45.2 (9.0–134.6) | 43.1 (9.0–107.8) | 47.1 (10.0–134.6) | 0.06 |
| Treatments, n (%) | <0.001 | |||
| none | 197 (20.0) | 0 (0.0) | 197 (22.3) | |
| ACEi or ARB | 778 (79.0) | 95 (95.0) | 683 (77.2) | |
| dual blockades | 10 (1.0) | 5 (5.0) | 5 (0.5) | |
| corticosteroids | 144 (14.6) | 65 (65.0) | 79 (8.9) |
All data are expressed as mean ± SD and median (range). UPCR, urinary protein-to-creatinine ratio; SCr, serum creatinine; eGFR, estimated GFR; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.